|
1
|
Bray F, Ferlay J, Soerjomataram I, Siegel
RL, Torre LA and Jemal A: Global cancer statistics 2018: GLOBOCAN
estimates of incidence and mortality worldwide for 36 cancers in
185 countries. CA Cancer J Clin. 68:394–424. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Gundem G, Van Loo P, Kremeyer B,
Alexandrov LB, Tubio JMC, Papaemmanuil E, Brewer DS, Kallio HML,
Högnäs G, Annala M, et al: The evolutionary history of lethal
metastatic prostate cancer. Nature. 520:353–357. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Schweizer MT, Wang H, Luber B, Nadal R,
Spitz A, Rosen DM, Cao H, Antonarakis ES, Eisenberger MA, Carducci
MA, et al: Bipolar androgen therapy for men with androgen ablation
naive prostate cancer: Results from the phase II BATMAN study.
Prostate. 76:1218–1226. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Morgans AK, Chen YH, Sweeney CJ, Jarrard
DF, Plimack ER, Gartrell BA, Carducci MA, Hussain M, Garcia JA,
Cella D, et al: Quality of life during treatment with chemohormonal
therapy: Analysis of E3805 chemohormonal androgen ablation
randomized trial in prostate cancer. J Clin Oncol. 36:1088–1095.
2018. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Sun S, Sprenger CC, Vessella RL, Haugk K,
Soriano K, Mostaghel EA, Page ST, Coleman IM, Nguyen HM, Sun H, et
al: Castration resistance in human prostate cancer is conferred by
a frequently occurring androgen receptor splice variant. J Clin
Invest. 120:2715–2730. 2010. View
Article : Google Scholar : PubMed/NCBI
|
|
6
|
Mercer TR, Dinger ME and Mattick JS: Long
non-coding RNAs: Insights into functions. Nat Rev Genet.
10:155–159. 2009. View
Article : Google Scholar : PubMed/NCBI
|
|
7
|
Engreitz JM, Ollikainen N and Guttman M:
Long non-coding RNAs: Spatial amplifiers that control nuclear
structure and gene expression. Nat Rev Mol Cell Biol. 17:756–770.
2016. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Dykes IM and Emanueli C: Transcriptional
and post-transcriptional gene regulation by long non-coding RNA.
Genomics Proteomics Bioinformatics. 15:177–186. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Gutschner T and Diederichs S: The
hallmarks of cancer: A long non-coding RNA point of view. RNA Biol.
9:703–719. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Spizzo R, Almeida MI, Colombatti A and
Calin GA: Long non-coding RNAs and cancer: A new frontier of
translational research? Oncogene. 31:4577–4587. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Zhang WY, Liu YJ, He Y and Chen P:
Suppression of long noncoding RNA NCK1-AS1 increases
chemosensitivity to cisplatin in cervical cancer. J Cell Physiol.
234:4302–4313. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Edge SB and Compton CC: The American joint
committee on cancer: The 7th edition of the AJCC cancer staging
manual and the future of TNM. Ann Surg Oncol. 17:1471–1474. 2010.
View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Epstein JI, Egevad L, Amin MB, Delahunt B,
Srigley JR, Humphrey PA and Grading Committee: The 2014
international society of urological pathology (ISUP) consensus
conference on gleason grading of prostatic carcinoma: Definition of
grading patterns and proposal for a new grading system. Am J Surg
Pathol. 40:244–252. 2016.PubMed/NCBI
|
|
14
|
Livak KJ and Schmittgen TD: Analysis of
relative gene expression data using real-time quantitative PCR and
the 2(-Delta Delta C(T)) method. Methods. 25:402–408. 2001.
View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Sanchez BE, Aguayo A, Martinez B,
Rodríguez F, Marmolejo M, Svyryd Y, Luna L, Muñoz LA, Jiménez MA,
Sotomayor M, et al: Using genetic and epigenetic markers to improve
differential diagnosis of prostate cancer and benign prostatic
hyperplasia by noninvasive methods in Mexican patients. Clin
Genitourin Cancer. 16:e867–e877. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Leidinger P, Hart M, Backes C, Rheinheimer
S, Keck B, Wullich B, Keller A and Meese E: Differential
blood-based diagnosis between benign prostatic hyperplasia and
prostate cancer: miRNA as source for biomarkers independent of PSA
level, gleason score, or TNM status. Tumour Biol. 37:10177–10185.
2016. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Qi P, Zhou XY and Du X: Circulating long
non-coding RNAs in cancer: Current status and future perspectives.
Mol Cancer. 15:392016. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Derynck R, Akhurst RJ and Balmain A:
TGF-beta signaling in tumor suppression and cancer progression. Nat
Genet. 29:117–129. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Yingling JM, Blanchard KL and Sawyer JS:
Development of TGF-beta signalling inhibitors for cancer therapy.
Nat Rev Drug Discov. 3:1011–1022. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Li Z, Dong M, Fan D, Hou P, Li H, Liu L,
Lin C, Liu J, Su L, Wu L, et al: LncRNA ANCR down-regulation
promotes TGF-β-induced EMT and metastasis in breast cancer.
Oncotarget. 8:67329–67343. 2017.PubMed/NCBI
|
|
21
|
Alarcón C, Zaromytidou AI, Xi Q, Gao S, Yu
J, Fujisawa S, Barlas A, Miller AN, Manova-Todorova K, Macias MJ,
et al: Nuclear CDKs drive Smad transcriptional activation and
turnover in BMP and TGF-beta pathways. Cell. 139:757–769. 2009.
View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Li H, Jia Y, Cheng J, Liu G and Song F:
LncRNA NCK1-AS1 promotes proliferation and induces cell cycle
progression by crosstalk NCK1-AS1/miR-6857/CDK1 pathway. Cell Death
Dis. 9:1982018. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Xia P, Huang M, Zhang Y, Xiong X, Yan M,
Xiong X, Yu W and Song E: NCK1 promotes the angiogenesis of
cervical squamous carcinoma via Rac1/PAK1/MMP2 signal pathway.
Gynecol Oncol. 152:387–395. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Benson MC, Whang IS, Pantuck A, Ring K,
Kaplan SA, Olsson CA and Cooner WH: Prostate specific antigen
density: A means of distinguishing benign prostatic hypertrophy and
prostate cancer. J Urol. 147:815–816. 1992. View Article : Google Scholar : PubMed/NCBI
|
